About Nuron Biotech

Nuron Biotech is developing novel biologics and vaccines for the prevention and treatment of neurodegenerative and infectious diseases. Our team of industry veterans is advancing products to meet unmet medical needs in the areas of multiple sclerosis, Alzheimer's, Hepatitis B and Hepatitis C for patients across the globe. Our lead drug candidate, NU100 (interferon beta-1b), is a new chemical entity currently in Phase 3 for patients with multiple sclerosis.

Claim this company page
Headquarters
Exton Pennsylvania, United States
Revenue
$7 Million
Employees
11 to 50
Industry
Links
Nuron Biotech website